Intestinal Failure-Associated Liver Disease
NorthSea Therapeutics B.V. focuses on clinical research in intestinal failure-associated liver disease (IFALD), with attention to the hepatic complications that arise in the setting of impaired intestinal function.
- Hepatic steatosis
- Hepatic inflammation
- Cholestasis
- Liver fibrosis
The sponsor’s research activity in this area also includes related clinical interest in bile acid metabolism and intestinal injury.
Gastrointestinal and Intestinal Function
Its trial portfolio includes assessment of colon function and broader intestinal function in relation to treatment effects and disease biology.
- Colon function
- Intestinal injury
- Gut-liver interactions
This area reflects a therapeutic interest in conditions where impaired intestinal physiology contributes to liver disease.
Metabolic and Lipid Pathways
NorthSea Therapeutics B.V. also examines biomarkers linked to lipid metabolism and glucose metabolism, indicating a strong focus on metabolic pathways relevant to IFALD.
- Lipid metabolism
- Glucose metabolism
- Metabolic biomarkers
These interests connect hepatic disease with systemic metabolic disturbance.
Pharmacokinetics and Pharmacodynamics
The sponsor’s clinical work includes evaluation of pharmacokinetics and pharmacodynamics alongside safety and tolerability in subjects with IFALD.
- Pharmacokinetic profiling
- Exposure-response relationships
- Non-invasive biomarkers
Biomarker assessments span hepatic, metabolic, and intestinal domains to characterize treatment-related biological effects.
Bile Acid and Incretin Biology
Research activity also extends to bile acid metabolism and circulating incretins, reflecting interest in endocrine and hepatobiliary mechanisms relevant to disease progression.
- Bile acid metabolism
- Circulating incretins
- Hepatic cholestasis
These domains support investigation of liver injury in the context of altered intestinal and metabolic signaling.
